Pangaea Oncology (XMAD:PANG) Asset Turnover: 0.24 (As of Dec. 2025)


XMAD:PANG Pangaea Oncology SA XMAD:PANG
63 GF Score
Price €1.51
GF Value €2.15
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Pangaea Oncology Asset Turnover?

Pangaea Oncology XMAD:PANG 63 Asset Turnover is 0.24 as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 63/100 and a GF Value™ of €2.15 (Possible Value Trap). The stock has 7 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Pangaea Oncology's Revenue for the six months ended in Dec. 2025 was €7.37 Mil. Pangaea Oncology's Total Assets for the quarter that ended in Dec. 2025 was €30.84 Mil. Therefore, Pangaea Oncology's Asset Turnover for the quarter that ended in Dec. 2025 was 0.24.

Asset Turnover is linked to ROE % through Du Pont Formula. Pangaea Oncology's annualized ROE % for the quarter that ended in Dec. 2025 was -18.30%. It is also linked to ROA % through Du Pont Formula. Pangaea Oncology's annualized ROA % for the quarter that ended in Dec. 2025 was -12.35%.

Pangaea Oncology  (XMAD:PANG) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Pangaea Oncology's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-3.808/20.8135
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-3.808 / 14.736)*(14.736 / 30.841)*(30.841/ 20.8135)
=Net Margin %*Asset Turnover*Equity Multiplier
=-25.84 %*0.4778*1.4818
=ROA %*Equity Multiplier
=-12.35 %*1.4818
=-18.30 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Pangaea Oncology's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-3.808/30.841
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-3.808 / 14.736)*(14.736 / 30.841)
=Net Margin %*Asset Turnover
=-25.84 %*0.4778
=-12.35 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

Pangaea Oncology Asset Turnover Related Terms

Pangaea Oncology Asset Turnover Historical Data

* Premium members only.

The historical data trend for Pangaea Oncology's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pangaea Oncology Asset Turnover Chart

Pangaea Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.18 0.26 0.47 0.45

Pangaea Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.24 0.26 0.23 0.24

XMAD:PANG vs TMO, DHR, IDXX: Asset Turnover Comparison

For the Diagnostics & Research subindustry, Pangaea Oncology's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pangaea Oncology Asset Turnover vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Pangaea Oncology's Asset Turnover falls into.


XMAD:PANG
63GF Score
Pangaea Oncology SA XMAD:PANG
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pangaea Oncology Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Pangaea Oncology's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=14.524/( (32.406+32.109)/ 2 )
=14.524/32.2575
=0.45

Pangaea Oncology's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=7.368/( (29.573+32.109)/ 2 )
=7.368/30.841
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.24 mean?
Pangaea Oncology (XMAD:PANG) has a Asset Turnover of 0.24 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Pangaea Oncology and its competitors.
Is Pangaea Oncology's Asset Turnover too high?
Pangaea Oncology's current Asset Turnover is 0.24. Overall, Pangaea Oncology has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Asset Turnover compare to TMO and DHR?
Pangaea Oncology's Asset Turnover of 0.24 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Medical Diagnostics & Research company?
A good Asset Turnover depends on the Medical Diagnostics & Research industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Pangaea Oncology and its competitors. Pangaea Oncology's current Asset Turnover is 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.15, compared to a current price of €1.51 — trading 29.8% below its estimated fair value. The current Asset Turnover is 0.24. Pangaea Oncology's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Asset Turnover is 0.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?

Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued. The current stock price of €1.51 is trading 29.8% below its estimated GF Value™ of €2.15. GuruFocus considers Pangaea Oncology to be Possible Value Trap.

Key valuation signals for XMAD:PANG:

  • Asset Turnover: 0.24
  • GF Value™: €2.15 vs. price of €1.51 (29.8% below fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pangaea Oncology Business Description

Address Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
63GF Score

Get the complete analysis for XMAD:PANG

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.51
Price
€2.15
GF Value